01 18Vectibix
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 204
2018 Revenue in Millions : 188
Growth (%) : 8
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 811
2019 Revenue in Millions : 744
Growth (%) : 9
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 873
2020 Revenue in Millions : 811
Growth (%) : 8
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 221
2019 Revenue in Millions : 208
Growth (%) : 6
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 209
2020 Revenue in Millions : 212
Growth (%) : 6
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 893
2021 Revenue in Millions : 873
Growth (%) : 2
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 196
2021 Revenue in Millions : 209
Growth (%) : -6
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 984
2022 Revenue in Millions : 893
Growth (%) : 10
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 179
2022 Revenue in Millions : 196
Growth (%) : 3
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 505
2014 Revenue in Millions : 549
Growth (%) : 9%
LOOKING FOR A SUPPLIER?
